Why the study?
Do oral anticoagulants (apixaban, dabigatran, rivaroxaban) reduce medical costs of clinical events compared to warfarin in NVAF patients with moderate and high stroke risk?
Do oral anticoagulants (apixaban, dabigatran, rivaroxaban) reduce medical costs of clinical events compared to warfarin in NVAF patients with moderate and high stroke risk?
Apixaban demonstrated consistent medical cost reductions compared to warfarin for NVAF patients with both moderate and high stroke risks from a US payer perspective.
No takes yet. Share an insight, caveat, or question.
Apixaban may reduce medical costs versus warfarin in moderate- and high-risk NVAF; leaves open practice change pending higher-level confirmation.
Deitelzweig et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: